公司发布的三季报数据显示，前三季度公司共实现营业收入14.01亿元，同比下降0.68%，实现净利润 1.28亿元，同比增长6.24%，基本每股收益为0.5500元，加权平均净资产收益率3.80%。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计显示，熵基科技所属的计算机行业，目前整体涨幅为0.66%，行业内，目前股价上 涨的有231只，涨幅居前的有岩山科技、熵基科技、星环科技等，涨幅分别为10.00%、8.50%、7.41%。 股价下跌的有107只，跌幅居前的有金橙子、首都在线、德生科技等，跌幅分别为5.65%、2.90%、 2.70%。 两融数据显示，该股最新（1月5日）两融余额为2.37亿元，其中，融资余额为2.37亿元，近10日增加 5509.89万元，环比增长30.34%。 熵基科技股价创出历史新高，截至9:38，该股上涨8.50%，股价报43.03元，成交量1566.84万股，成交金 额7.08亿元，换手率13.75%，该股最新A股总市值达101.27亿元，该股A股流通市值49.02亿元。 ...

Group 1 - In the past five trading days, a total of 188 companies were investigated by institutions, with a significant focus on companies like Mindray Medical, CITIC Securities, and Entropy Technology [1] - Among the companies investigated, 57 received attention from more than 20 institutions, with Mindray Medical being the most popular, attracting 205 institutions [1] - The types of institutions involved in the investigations included 171 securities companies, 140 fund companies, and 92 private equity firms, indicating a strong interest from the securities sector [1] Group 2 - In terms of capital inflow, 24 stocks that were investigated by more than 20 institutions saw net capital inflows, with CITIC Securities receiving the highest net inflow of 669 million yuan [1] - Other notable companies with significant net inflows included Zhongke Jiangnan and Entropy Technology, with net inflows of 280 million yuan and 259 million yuan, respectively [1] - The stocks that experienced price increases included Haoshi Electromechanical, Entropy Technology, and Zhongke Jiangnan, with respective gains of 39.71%, 34.81%, and 30.25% [2] Group 3 - The most frequently investigated company was Entropy Technology, which was surveyed three times by institutions, while companies like Jiuli Special Materials and Aidi Tech were surveyed twice [1] - The investigation data also highlighted that 41 stocks among those investigated saw price increases, while 16 experienced declines, with the largest drop being 12.17% for Shenghui Integration [2] - A detailed list of companies investigated included Mindray Medical, CITIC Securities, and Entropy Technology, along with their respective closing prices and percentage changes [2][3]

每经AI快讯，1月6日早盘，脑机接口概念延续强势，岩山科技（002195）、南京熊猫（600775）、创 新医疗（002173）、倍益康、美好医疗（301363）、三博脑科（301293）封涨停，爱朋医疗 （300753）、熵基科技（301330）、翔宇医疗、伟思医疗等高开超10%。 ...

Core Viewpoint - The company is progressing as planned with its brain-machine prototype, focusing on marketing and brand promotion, which is not expected to significantly impact overall revenue in the short term [1] Group 1: Company Developments - The brain-machine business is viewed positively for its market potential, although its contribution to future revenue and performance remains uncertain [1]

Group 1: Company Overview and Business Focus - The company specializes in brain-machine interface (BMI) technology, focusing on sectors such as healthcare, education, and elderly care [3][4] - The company is leveraging advanced multimodal visual analysis technologies to enhance its BMI capabilities [4] Group 2: Development and Market Strategy - The establishment of the joint venture for the brain-machine company is currently in the registration phase with foreign partners [3] - The company plans to launch a brain-machine prototype in March 2026, with initial marketing efforts aimed at brand promotion [4] - The BMI business will target both existing clients in healthcare and education and new customers in consumer electronics, industrial, and research sectors [5] Group 3: Financial Projections and Commitments - The company has a performance commitment with Longzhiyuan, expecting a net profit of no less than RMB 90 million in 2025 [6] - The revenue impact from the brain-machine business is uncertain, although the company is optimistic about its market potential [4]

从资金流向上来看，当日数字经济板块主力资金净流出8.89亿元，游资资金净流出15.82亿元，散户资金 净流入24.72亿元。数字经济板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月5日数字经济板块较上一交易日上涨1.97%，熵基科技领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。数字经济板块个股涨跌见下表： ...

股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 证券代码：301330 证券简称：熵基科技 公告编号：2026-001 熵基科技股份有限公司 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意 向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市规 则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产 生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 熵基科技股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日、2025 年 12 月 31 日和 2026 年 1 月 5 日连续三个交易日收盘价涨跌幅偏离值累计超过 30%。根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动的 情况。 二、公司关注并核实情况的说明 针对公司股票交易异常波动情况，公司对有关情况进行了核查，并向控股股 东及实际控制人函询，现就相关情况说明如下： 1、公司前期披露的信息 ...

截至1月5日收盘，辅助生殖概念上涨4.45%，位居概念板块涨幅第9，板块内，69股上涨，谱尼测试、 熵基科技、麦澜德等20%涨停，国际医学、众生药业、福元医药等涨停，采纳股份、兰卫医学、迪安诊 断等涨幅居前，分别上涨11.05%、10.27%、8.08%。跌幅居前的有思创医惠、明德生物、ST香雪等，分 别下跌4.74%、1.20%、0.11%。 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002317 | 众生药 业 | 10.01 | 10.86 | 29260.43 | 17.57 | | 301330 | 熵基科 技 | 20.00 | 17.61 | 20993.04 | 27.06 | | 000516 | 国际医 学 | 10.02 | 2.62 | 11125.36 | 41.60 | | 300887 | 谱尼测 试 | 20.00 | 18.18 | 10773.41 | 15.14 | | 600 ...

Core Viewpoint - The A-share market experienced a significant upward movement on the first trading day of 2026, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark, driven by a surge in brain-computer interface (BCI) stocks [1] Group 1: Market Performance - The combined trading volume of the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, indicating a notable increase in market activity [1] - Several BCI-related stocks, including Sanbo Brain Science, Aipeng Medical, and others, reached the daily limit of a 20% increase [1][2] Group 2: Industry Insights - Elon Musk's recent comments regarding Neuralink's plans to mass-produce BCI devices by 2026 have sparked interest in the BCI sector, with expectations of significant advancements in technology and applications [3] - The global BCI market is projected to grow from $2.94 billion in 2025 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [3] - Recent research breakthroughs in medical applications such as movement recovery and communication have been reported, supported by favorable policies from the government, including separate pricing for new BCI technologies [4]

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...